Literature DB >> 31418320

Prognostic impact of socioeconomic status among patients with malignant melanoma of the skin: a population-based study.

Omar Abdel-Rahman1.   

Abstract

Objective: To assess the prognostic impact of socioeconomic status (SES) on the outcome of cases with cutaneous melanoma.
Methods: Novel SEER socioeconomic database has been accessed and patients with malignant melanoma of the skin (2000-2015) were reviewed. SES was evaluated through a specialized multi-dimension index and patients were classified into three groups (group 1/2/3) where group 1 has the lowest SES and group 3 has the highest SES. Kaplan-Meier survival estimates were used to evaluate the impact of SES on overall survival and multivariable Cox regression analysis was used to assess the impact of SES on melanoma-specific survival.
Results: A total of 261,076 patients with malignant melanoma of the skin were included in the current study. Among which, 44,804 patients were within group 1 SES, 84,168 patients were within group 2 SES and 132,104 patients were within group 3 SES. Kaplan-Meier survival analysis was performed, and it showed that patients with lower SES have worse overall survival (p < .001). Multivariable Cox regression analysis was subsequently performed, and it showed also that lower SES is associated with worse melanoma-specific survival (hazard ratio for group 1 versus group 3 SES: 1.361; 95% CI: 1.315-1.409; p < .001).
Conclusion: Patients with cutaneous melanoma and lower SES have worse overall and melanoma-specific survival compared to patients with higher SES. This finding was consistent among different clinical subsets of patients according to stage, race/ethnicity, and year of diagnosis.

Entities:  

Keywords:  Malignant melanoma; education; income; prognosis

Mesh:

Year:  2019        PMID: 31418320     DOI: 10.1080/09546634.2019.1657223

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN: 0954-6634            Impact factor:   3.359


  8 in total

1.  Melanoma in women of childbearing age and in pregnancy in California, 1994-2015: a population-based cohort study.

Authors:  M Kiuru; Q Li; G Zhu; J R Terrell; K Beroukhim; E Maverakis; T H M Keegan
Journal:  J Eur Acad Dermatol Venereol       Date:  2022-08-23       Impact factor: 9.228

Review 2.  Racial and Ethnic Healthcare Disparities in Skin Cancer in the United States: A Review of Existing Inequities, Contributing Factors, and Potential Solutions.

Authors:  Kimberly Shao; Hao Feng
Journal:  J Clin Aesthet Dermatol       Date:  2022-07

3.  The ongoing racial disparities in melanoma: An analysis of the Surveillance, Epidemiology, and End Results database (1975-2016).

Authors:  Yingzhi Qian; Paul Johannet; Amelia Sawyers; Jaehong Yu; Iman Osman; Judy Zhong
Journal:  J Am Acad Dermatol       Date:  2020-08-27       Impact factor: 11.527

4.  A Novel Nomogram and Risk Classification System Predicting the Cancer-Specific Mortality of Patients with Initially Diagnosed Metastatic Cutaneous Melanoma.

Authors:  Wei Li; Yang Xiao; Xuewen Xu; Yange Zhang
Journal:  Ann Surg Oncol       Date:  2020-11-15       Impact factor: 5.344

5.  Patterns of cost-related medication underuse among Canadian adults with cancer: a cross-sectional study using survey data.

Authors:  Omar Abdel-Rahman; Scott North
Journal:  CMAJ Open       Date:  2021-05-06

6.  Socioeconomic Determinants of Melanoma-Related Health Literacy and Attitudes Among College Students in China: A Population-Based Cross-Sectional Study.

Authors:  Tianhao Wu; Xianggui Wang; Shuang Zhao; Yi Xiao; Minxue Shen; Xi Han; Xiang Chen; Juan Su
Journal:  Front Public Health       Date:  2021-11-11

7.  Racial Differences in the Prognosis and Survival of Cutaneous Melanoma From 1990 to 2020 in North America: A Systematic Review and Meta-Analysis.

Authors:  Megan Lam; Jie Wei Zhu; Angie Hu; Jennifer Beecker
Journal:  J Cutan Med Surg       Date:  2021-10-22       Impact factor: 2.092

8.  Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis from 2014 to 2016.

Authors:  Tamara A Sussman; Rebecca Knackstedt; Wei Wei; Pauline Funchain; Brian R Gastman
Journal:  J Immunother Cancer       Date:  2022-08       Impact factor: 12.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.